Gilead Sciences
GILD
2,026 hedge funds and large institutions have $117B invested in Gilead Sciences in 2025 Q3 according to their latest regulatory filings, with 164 funds opening new positions, 828 increasing their positions, 726 reducing their positions, and 128 closing their positions.
28% more first-time investments, than exits
New positions opened: 164 | Existing positions closed: 128
17% more call options, than puts
Call options by funds: $1B | Put options by funds: $855M
14% more repeat investments, than reductions
Existing positions increased: 828 | Existing positions reduced: 726
0% more funds holding
Funds holding: 2,023 → 2,026 (+3)
2% less capital invested
Capital invested by funds: $119B → $117B (-$1.87B)
1.27% less ownership
Funds ownership: 86.42% → 85.16% (-1.3%)
42% less funds holding in top 10
Funds holding in top 10: 33 → 19 (-14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$332M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$315M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$247M |
| 4 |
JP Morgan Chase
New York
|
+$237M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$213M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.35B |
| 2 |
UBS AM
Chicago,
Illinois
|
-$409M |
| 3 |
Amundi
Paris,
France
|
-$328M |
| 4 |
Holocene Advisors
New York
|
-$183M |
| 5 |
Axa
Paris,
France
|
-$178M |
GILD Hedge Fund Activity: Q3 2025 in Review
2,026 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2025, worth a combined $117B — down 1.6% from $119B a quarter earlier.
Buyers outnumbered sellers: 164 funds opened new GILD positions and 128 closed out — a net gain of 36 holders — while 828 added to existing stakes and 726 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $332M. The largest seller was Wellington Management Group, cutting an estimated $1.35B.
- 2,026 institutional investors held Gilead Sciences (GILD) as of Q3 2025, up from 2,023 in Q2 2025.
- Funds reported $117B of Gilead Sciences stock for Q3 2025, down 1.6% quarter-over-quarter.
- 164 funds opened new Gilead Sciences positions in Q3 2025 and 128 closed out, a net change of +36 holders.
- The largest Gilead Sciences buyer in Q3 2025 was T. Rowe Price Associates, an estimated $332M added.
- The largest Gilead Sciences seller in Q3 2025 was Wellington Management Group, an estimated $1.35B sold.
Based on aggregated 13F filings for Q3 2025.